Bionomics Ltd - Product Pipeline Review - 2016

Date: December 30, 2016
Pages: 47
Price:
US$ 1,500.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: BDC687CCD9BEN
Leaflet:

Download PDF Leaflet

Bionomics Ltd - Product Pipeline Review - 2016
Bionomics Ltd - Product Pipeline Review - 2016

SUMMARY

Global Markets Direct’s, ‘Bionomics Ltd - Product Pipeline Review - 2016’, provides an overview of the Bionomics Ltd’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Bionomics Ltd, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

SCOPE
  • The report provides a snapshot of the pipeline therapeutic landscape of Bionomics Ltd
  • The report provides overview of Bionomics Ltd including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Bionomics Ltd’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Bionomics Ltd’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
REASONS TO BUY
  • Evaluate Bionomics Ltd’s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Bionomics Ltd
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Bionomics Ltd’s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Bionomics Ltd Snapshot
Bionomics Ltd Overview
Key Facts
Bionomics Ltd - Research and Development Overview
Key Therapeutic Areas
Bionomics Ltd - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Out-Licensed Products
Out-Licensed Products/Combination Treatment Modalities
Bionomics Ltd - Pipeline Products Glance
Bionomics Ltd - Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Bionomics Ltd - Early Stage Pipeline Products
IND/CTA Filed Products/Combination Treatment Modalities
Preclinical Products/Combination Treatment Modalities
Bionomics Ltd - Drug Profiles
BL-011256 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BNC-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BNC-105 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BNC-164 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BNC-210 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BNC-420 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug for Dyskinesia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug for Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs for Solid Tumors - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs to Inhibit MELK for Solid Tumors - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize GABA-A Receptor For Epilepsy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Block Nav 1.7 Channels for Chronic And Neuropathic Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bionomics Ltd - Pipeline Analysis
Bionomics Ltd - Pipeline Products by Target
Bionomics Ltd - Pipeline Products by Route of Administration
Bionomics Ltd - Pipeline Products by Molecule Type
Bionomics Ltd - Pipeline Products by Mechanism of Action
Bionomics Ltd - Dormant Projects
Bionomics Ltd - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
Drug to Inhibit RET Kinase for Lung and Thyroid Cancer
Bionomics Ltd - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Bionomics Ltd, Key Facts
Bionomics Ltd - Pipeline by Indication, 2016
Bionomics Ltd - Pipeline by Stage of Development, 2016
Bionomics Ltd - Monotherapy Products in Pipeline, 2016
Bionomics Ltd - Out-Licensed Products in Pipeline, 2016
Bionomics Ltd - Out-Licensed Products/ Combination Treatment Modalities, 2016
Bionomics Ltd - Phase II, 2016
Bionomics Ltd - Phase I, 2016
Bionomics Ltd - IND/CTA Filed, 2016
Bionomics Ltd - Preclinical, 2016
Bionomics Ltd - Pipeline by Target, 2016
Bionomics Ltd - Pipeline by Route of Administration, 2016
Bionomics Ltd - Pipeline by Molecule Type, 2016
Bionomics Ltd - Pipeline Products by Mechanism of Action, 2016
Bionomics Ltd - Dormant Developmental Projects,2016
Bionomics Ltd - Discontinued Pipeline Products, 2016
Bionomics Ltd, Subsidiaries

LIST OF FIGURES

Bionomics Ltd - Pipeline by Top 10 Indication, 2016
Bionomics Ltd - Pipeline by Stage of Development, 2016
Bionomics Ltd - Monotherapy Products in Pipeline, 2016
Bionomics Ltd - Pipeline by Target, 2016
Bionomics Ltd - Pipeline by Route of Administration, 2016
Bionomics Ltd - Pipeline by Molecule Type, 2016
Bionomics Ltd - Pipeline Products by Mechanism of Action, 2016
Skip to top


QRxPharma Limited - Product Pipeline Review - 2014 US$ 1,500.00 Jun, 2014 · 42 pages

Ask Your Question

Bionomics Ltd - Product Pipeline Review - 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: